Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PWT-143 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | 3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required. |
| Part 2 | EXPERIMENTAL | Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects. |
| Name | Type | Description |
|---|---|---|
| PWT-143 | DRUG | phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor |
Inclusion Criteria: 1. Healthy males 2. Age 18 to 65 years of age 3. Body mass index of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator 4. Part 2 only: Must be able to consume all food items in a standard high fat breakfast and/or have no condi...
PWT-143 is an investigational small molecule being developed for the treatment of malignancies, which are cancers or tumors. It is currently in Phase 1 clinical development, meaning it is being studied for safety and tolerability in humans. It is not yet approved by regulatory authorities.
PWT-143 is being developed by Lite Strategy, Inc., a company traded under the ticker symbol LITS. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with malignancies.
PWT-143 is in Phase 1 clinical development. A Phase 1 trial has been completed, which assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of various formulations and doses of the drug in patients with malignancies.
PWT-143 has one completed Phase 1 clinical trial, identified as NCT02521389. This trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of various formulations and doses of PWT-143 in patients with malignancies. The trial enrolled 35 participants in the United Kingdom.
No alternative names for PWT-143 have been reported. It is identified solely by its code name PWT-143 in clinical trial registries and development programs.